{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:56Z","timestamp":1781636096114,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2023QH431"],"award-info":[{"award-number":["ZR2023QH431"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2021MH050"],"award-info":[{"award-number":["ZR2021MH050"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Youth Fund of the National Natural Science Foundation of China","award":["82102945"],"award-info":[{"award-number":["82102945"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aggressive cancer known as pancreatic ductal adenocarcinoma (PDAC) has a remarkably poor response to treatment, especially gemcitabine (GEM). As a member of the noncanonical I\u03baB kinase family, inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) is known to regulate tumor progression in multiple cancer types. However, its functional role in modulating chemosensitivity and its impact on cell death pathways in PDAC remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We examined IKBKE expression in patient tumor tissues and publicly available databases and assessed its prognostic value to investigate its function in PDAC chemoresistance. Loss-of-function approaches, including shRNA knockdown and pharmacological inhibition using amlexanox, were employed in vivo and in vitro. Furthermore, cytotoxicity along with cell death patterns induced by GEM were assessed through flow cytometry, electron microscopy, and CCK-8 assays. Co-IP and GST pull-down assays were applied to determine whether IKBKE interacts with gasdermin E (GSDME), the executioner protein of pyroptosis. Moreover, in vitro kinase assays, phosphorylation mass spectrometry, and site-specific gain-\/loss-of-function mutant functional experiments were conducted to investigate the specific pathways via which IKBKE affects GSDME-mediated pyroptosis. The therapeutic potential of IKBKE targeting was further validated using patient-derived tumor organoids and xenograft models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IKBKE was significantly elevated in PDAC tissues and was closely linked to worse clinical outcomes. Functional studies of the signaling pathway showed that via the activation of the protein kinase B\/glycogen synthase kinase-3\u03b2 signaling pathway, IKBKE facilitates the aggressive phenotype of PDAC cells. IKBKE inhibition or silencing increased GEM sensitivity and caused caspase-3\/GSDME-dependent pyroptosis in PDAC cells. Co-IP and GST pull-down analysis revealed IKBKE\u2013GSDME interaction. Further in vitro cleavage and kinase assays, mass spectrometry analysis, and mutant functional studies showed that IKBKE inhibits pyroptosis by phosphorylating GSDME at Thr6, thereby hindering its cleavage by caspase-3. Treatment with amlexanox markedly suppressed tumor growth and synergized with GEM to enhance anti-tumor efficacy in organoid models by targeting IKBKE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings identify IKBKE as a key regulator of chemotherapy-induced pyroptosis in PDAC. Specifically, IKBKE phosphorylates GSDME at Thr6, which alters its conformation, thereby impeding caspase-3\u2013mediated cleavage, ultimately contributing to GEM chemoresistance. IKBKE targeting reverses GEM resistance and enhances tumor immunogenic cell death via the caspase-3\/GSDME pathway, supporting IKBKE inhibition as a promising therapeutic strategy for PDAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03670-1","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:34:55Z","timestamp":1771220095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IKBKE downregulation increases chemosensitivity through pyroptosis mediated by the caspase-3\/GSDME pathway in pancreatic cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Ting","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"3670_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000455736","volume":"26","author":"J Dhillon","year":"2020","unstructured":"Dhillon J, Betancourt M. Pancreatic ductal adenocarcinoma. Monogr Clin Cytol. 2020;26:74\u201391.","journal-title":"Monogr Clin Cytol"},{"issue":"3","key":"3670_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Ca-Cancer J Clin"},{"issue":"3","key":"3670_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Ca-Cancer J Clin"},{"key":"3670_CR4","doi-asserted-by":"publisher","first-page":"102180","DOI":"10.1016\/j.ctrv.2021.102180","volume":"96","author":"S De Dosso","year":"2021","unstructured":"De Dosso S, Siebenhuner AR, Winder T, Meisel A, Fritsch R, Astaras C, et al. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev. 2021;96:102180.","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"3670_CR5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med. 2011;364(19):1817\u201325.","journal-title":"New Engl J Med"},{"issue":"22","key":"3670_CR6","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.2174\/0929867324666170209104453","volume":"25","author":"A Mohammed","year":"2018","unstructured":"Mohammed A, Janakiram NB, Madka V, Li M, Asch AS, Rao CV. Current challenges and opportunities for chemoprevention of pancreatic cancer. Curr Med Chem. 2018;25(22):2535\u201344.","journal-title":"Curr Med Chem"},{"issue":"10242","key":"3670_CR7","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008\u201320.","journal-title":"Lancet"},{"issue":"1","key":"3670_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cam4.2678","volume":"9","author":"M Yin","year":"2020","unstructured":"Yin M, Wang X, Lu J. Advances in IKBKE as a potential target for cancer therapy. Cancer Med-Us. 2020;9(1):247\u201358.","journal-title":"Cancer Med-Us"},{"issue":"3","key":"3670_CR9","first-page":"2897","volume":"18","author":"X Gao","year":"2019","unstructured":"Gao X, Wang M, Zhang Y, Xu Z, Ding J, Tang J. MicroRNA-16 sensitizes drug-resistant breast cancer cells to adriamycin by targeting Wip1 and Bcl-2. Oncol Lett. 2019;18(3):2897\u2013906.","journal-title":"Oncol Lett"},{"issue":"1","key":"3670_CR10","first-page":"169","volume":"41","author":"H Li","year":"2012","unstructured":"Li H, Chen L, Zhang A, Wang G, Han L, Yu K, et al. Silencing of IKKepsilon using SiRNA inhibits proliferation and invasion of glioma cells in vitro and in vivo. Int J Oncol. 2012;41(1):169\u201378.","journal-title":"Int J Oncol"},{"issue":"7","key":"3670_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3109\/00313020903257756","volume":"41","author":"MR Kang","year":"2009","unstructured":"Kang MR, Kim MS, Kim SS, Ahn CH, Yoo NJ, Lee SH. NF-kappaB signalling proteins p50\/p105, p52\/p100, RelA, and IKKepsilon are over-expressed in oesophageal squamous cell carcinomas. Pathology. 2009;41(7):622\u20135.","journal-title":"Pathology"},{"issue":"10","key":"3670_CR12","doi-asserted-by":"publisher","first-page":"16233","DOI":"10.18632\/oncotarget.9069","volume":"8","author":"SE Lee","year":"2017","unstructured":"Lee SE, Hong M, Cho J, Lee J, Kim KM. IKKepsilon and TBK1 expression in gastric cancer. Oncotarget. 2017;8(10):16233\u201342.","journal-title":"Oncotarget"},{"issue":"5","key":"3670_CR13","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1159\/000373991","volume":"35","author":"D Tang","year":"2015","unstructured":"Tang D, Sun B, Yu H, Yang Z, Zhu L. Tumor-suppressing effect of miR-4458 on human hepatocellular carcinoma. Cell Physiol Biochem. 2015;35(5):1797\u2013807.","journal-title":"Cell Physiol Biochem"},{"key":"3670_CR14","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.2147\/CMAR.S204924","volume":"11","author":"X Wang","year":"2019","unstructured":"Wang X, Teng F, Lu J, Mu D, Zhang J, Yu J. Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancer. Cancer Manag Res. 2019;11:6593\u2013602.","journal-title":"Cancer Manag Res"},{"issue":"29","key":"3670_CR15","doi-asserted-by":"publisher","first-page":"eabb0616","DOI":"10.1126\/sciadv.abb0616","volume":"6","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Li Y, Liu H, Jain A, Patel PV, Cheng K. Co-delivery of IKBKE SiRNA and Cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer. Sci Adv. 2020;6(29):eabb0616.","journal-title":"Sci Adv"},{"issue":"8","key":"3670_CR16","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s12094-019-02251-3","volume":"22","author":"G Guo","year":"2020","unstructured":"Guo G, Sun Y, Hong R, Xiong J, Lu Y, Liu Y, et al. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Clin Transl Oncol. 2020;22(8):1252\u201362.","journal-title":"Clin Transl Oncol"},{"issue":"3 Pt 2","key":"3670_CR17","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.lpm.2019.02.025","volume":"48","author":"C Springfeld","year":"2019","unstructured":"Springfeld C, Jager D, Buchler MW, Strobel O, Hackert T, Palmer DH, et al. Chemotherapy for pancreatic cancer. Presse Med. 2019;48(3 Pt 2):e159\u201374.","journal-title":"Presse Med"},{"issue":"26","key":"3670_CR18","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1056\/NEJM200406243502617","volume":"350","author":"S Bydder","year":"2004","unstructured":"Bydder S, Spry N. Chemotherapy for pancreatic cancer. New Engl J Med. 2004;350(26):2713\u20135.","journal-title":"New Engl J Med"},{"issue":"17","key":"3670_CR19","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.7314\/APJCP.2014.15.17.7119","volume":"15","author":"IV Bayoglu","year":"2014","unstructured":"Bayoglu IV, Varol U, Yildiz I, Muslu U, Alacacioglu A, Kucukzeybek Y, et al. Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer. Asian Pac J Cancer Prev. 2014;15(17):7119\u201323.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3670_CR20","doi-asserted-by":"publisher","unstructured":"ZengS, Pottler M, Lan B, Grutzmann R, Pilarsky C, Yang H. Chemoresistance in pancreatic cancer. Int J Mol Sci. 2019;20(18):4504. https:\/\/doi.org\/10.3390\/ijms20184504.","DOI":"10.3390\/ijms20184504"},{"issue":"6","key":"3670_CR21","first-page":"e1289","volume":"3","author":"K Iede","year":"2020","unstructured":"Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, et al. Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer. Cancer Rep-Us. 2020;3(6):e1289.","journal-title":"Cancer Rep-Us"},{"issue":"5","key":"3670_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41419-024-06729-z","volume":"15","author":"Y Du","year":"2024","unstructured":"Du Y, Yang Z, Shi H, Chen Z, Chen R, Zhou F, et al. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA. Cell Death Dis. 2024;15(5):340.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3670_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1756-9966-30-87","volume":"30","author":"RS Wong","year":"2011","unstructured":"Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Canc Res. 2011;30(1):87.","journal-title":"J Exp Clin Canc Res"},{"key":"3670_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41420-020-00349-0","volume":"6","author":"M Jiang","year":"2020","unstructured":"Jiang M, Qi L, Li L, Li Y. The caspase-3\/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer. Cell Death Discov. 2020;6:112.","journal-title":"Cell Death Discov"},{"key":"3670_CR25","doi-asserted-by":"publisher","unstructured":"TsuchiyaK. Switching from apoptosis to pyroptosis: Gasdermin-Elicited inflammation and antitumor immunity. Int J Mol Sci. 2021;22(1):426. https:\/\/doi.org\/10.3390\/ijms22010426.","DOI":"10.3390\/ijms22010426"},{"key":"3670_CR26","doi-asserted-by":"publisher","first-page":"14128","DOI":"10.1038\/ncomms14128","volume":"8","author":"C Rogers","year":"2017","unstructured":"Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri ES. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic\/pyroptotic cell death. Nat Commun. 2017;8:14128.","journal-title":"Nat Commun"},{"issue":"7661","key":"3670_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature22393","volume":"547","author":"Y Wang","year":"2017","unstructured":"Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99\u2013103.","journal-title":"Nature"},{"issue":"6","key":"3670_CR28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s42255-024-01047-2","volume":"6","author":"Y Meng","year":"2024","unstructured":"Meng Y, Guo D, Lin L, Zhao H, Xu W, Luo S, et al. Glycolytic enzyme PFKL governs lipolysis by promoting lipid droplet-mitochondria tethering to enhance \u03b2-oxidation and tumor cell proliferation. Nat Metab. 2024;6(6):1092\u2013107.","journal-title":"Nat Metab"},{"issue":"8","key":"3670_CR29","doi-asserted-by":"publisher","first-page":"e3022","DOI":"10.1038\/cddis.2017.396","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, Lu J, Zhang Z, Zhu L, Dong S, Guo G, et al. Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines. Cell Death Dis. 2017;8(8):e3022.","journal-title":"Cell Death Dis"},{"issue":"7","key":"3670_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407\u201318.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3670_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","volume":"22","author":"M Labrie","year":"2022","unstructured":"Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer. 2022;22(6):323\u201339.","journal-title":"Nat Rev Cancer"},{"key":"3670_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2018.11.034","volume":"443","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Wang Z, Huang K, Liu Y, Wei C, Zhou J, et al. PLK4 is a determinant of Temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. Cancer Lett. 2019;443:91\u2013107.","journal-title":"Cancer Lett"},{"issue":"9791","key":"3670_CR33","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607\u201320.","journal-title":"Lancet"},{"key":"3670_CR34","doi-asserted-by":"publisher","first-page":"216206","DOI":"10.1016\/j.canlet.2023.216206","volume":"564","author":"S Li","year":"2023","unstructured":"Li S, Yue M, Xu H, Zhang X, Mao T, Quan M, et al. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Cancer Lett. 2023;564:216206.","journal-title":"Cancer Lett"},{"issue":"11","key":"3670_CR35","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41419-023-06247-4","volume":"14","author":"L Shi","year":"2023","unstructured":"Shi L, Zha H, Pan Z, Wang J, Xia Y, Li H, et al. DUSP1 protects against ischemic acute kidney injury through stabilizing MtDNA via interaction with JNK. Cell Death Dis. 2023;14(11):724.","journal-title":"Cell Death Dis"},{"issue":"12","key":"3670_CR36","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41422-023-00848-6","volume":"33","author":"Y Ai","year":"2023","unstructured":"Ai Y, Wang W, Liu F, Fang W, Chen H, Wu L, et al. Mannose antagonizes GSDME-mediated pyroptosis through AMPK activated by metabolite GlcNAc-6P. Cell Res. 2023;33(12):904\u201322.","journal-title":"Cell Res"},{"issue":"36","key":"3670_CR37","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1200\/JCO.22.02777","volume":"41","author":"HR Burris","year":"2023","unstructured":"Burris HR, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as First-Line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 2023;41(36):5482\u201392.","journal-title":"J Clin Oncol"},{"key":"3670_CR38","doi-asserted-by":"publisher","unstructured":"AdamskaA, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci. 2017;18(7):1338. https:\/\/doi.org\/10.3390\/ijms18071338.","DOI":"10.3390\/ijms18071338"},{"issue":"17","key":"3670_CR39","doi-asserted-by":"publisher","first-page":"E1038","DOI":"10.1073\/pnas.1114168109","volume":"109","author":"M Rajurkar","year":"2012","unstructured":"Rajurkar M, De Jesus-Monge WE, Driscoll DR, Appleman VA, Huang H, Cotton JL, et al. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. P Natl Acad Sci Usa. 2012;109(17):E1038\u201347.","journal-title":"P Natl Acad Sci Usa"},{"issue":"24","key":"3670_CR40","doi-asserted-by":"publisher","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-16-1666","volume":"76","author":"H Zubair","year":"2016","unstructured":"Zubair H, Azim S, Srivastava SK, Ahmad A, Bhardwaj A, Khan MA, et al. Glucose metabolism reprogrammed by overexpression of IKKepsilon promotes pancreatic tumor growth. Cancer Res. 2016;76(24):7254\u201364.","journal-title":"Cancer Res"},{"issue":"1","key":"3670_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1309\/AJCP2JJGYNIUAS2V","volume":"136","author":"A Cheng","year":"2011","unstructured":"Cheng A, Guo J, Henderson-Jackson E, Kim D, Malafa M, Coppola D. IkappaB kinase epsilon expression in pancreatic ductal adenocarcinoma. Am J Clin Pathol. 2011;136(1):60\u20136.","journal-title":"Am J Clin Pathol"},{"issue":"16","key":"3670_CR42","doi-asserted-by":"publisher","first-page":"13840","DOI":"10.1074\/jbc.M110474200","volume":"277","author":"N Kishore","year":"2002","unstructured":"Kishore N, Huynh QK, Mathialagan S, Hall T, Rouw S, Creely D, et al. IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK-2: comparative analysis of Recombinant human IKK-i, TBK-1, and IKK-2. J Biol Chem. 2002;277(16):13840\u20137.","journal-title":"J Biol Chem"},{"issue":"3","key":"3670_CR43","first-page":"a000158","volume":"2","author":"A Isra\u00ebl","year":"2010","unstructured":"Isra\u00ebl A. The IKK complex, a central regulator of NF-kappaB activation. Csh Perspect Biol. 2010;2(3):a000158.","journal-title":"Csh Perspect Biol"},{"issue":"8","key":"3670_CR44","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/s41418-022-00940-1","volume":"29","author":"W Xie","year":"2022","unstructured":"Xie W, Jiang Q, Wu X, Wang L, Gao B, Sun Z, et al. IKBKE phosphorylates and stabilizes snail to promote breast cancer invasion and metastasis. Cell Death Differ. 2022;29(8):1528\u201340.","journal-title":"Cell Death Differ"},{"key":"3670_CR45","doi-asserted-by":"publisher","first-page":"215864","DOI":"10.1016\/j.canlet.2022.215864","volume":"548","author":"L Wu","year":"2022","unstructured":"Wu L, Ge Y, Yuan Y, Li H, Sun H, Xu C, et al. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Cancer Lett. 2022;548:215864.","journal-title":"Cancer Lett"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03670-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03670-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03670-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:17:53Z","timestamp":1781633873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03670-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3670"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03670-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was authorized by the Ethics Committee of Shandong First Medical University Affiliated Provincial Hospital (NSFC: NO. 2021\u2009\u2212\u2009767 and 2023\u2009\u2212\u2009174). All methods were carried out in compliance with the applicable guidelines and regulations. All participant gave their informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The publication of this work has been authorized by all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}